Deutsche Bank has a Hold rating and a $88 price target on shares of Lorillard LO.
In a note to clients, Deutsche Bank writes, "Our view remains a ban is not the most likely outcome, but visibility is
low, and one cannot overlook that the advisory panel has made a negative recommendation. This could be difficult to circumvent, and the closer we get to a decision, the stronger one's conviction must be of no FDA follow-
through. After yesterday's move, LO appears more exposed to downside vs. upside risk from the process, as we estimate it now discounts < 10% probability of a ban."
Shares of LO gained $12.02 yesterday to close at $113.59, a gain of 11.8%.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in